Biomarkers and Precision Medicine Community (BPMC)

Detection and Quantification of On- and Off-target Genome Editing Events for Gene and Cell Therapy Drug Development

• What is the workflow of detecting off-target genome editing activities during preclinical and clinical studies?
• What are the different unbiased and targeted methodologies to detect on- and off-target genome editing outcomes?
• What are the critical analytical parameters when quantifying on-target and validated off-target editing frequencies during clinical studies?

Discussion Leaders:

Yanmei Lu (Sangamo Therapeutics), Ling Lin (Beam Therapeutics) and Cicera Lazzarotto (Beam Therapeutics)

Organized by:  

Yanmei Lu (Sangamo Therapeutics), Priya Chockalingam (Beam Therapeutics), Yan Ni (Passage Bio), Carmen Fernández-Metzler (PharmaCadence), Karen Quadrini (Passage Bio), and Sanjeev Bhardwaj (Moderna)